Cabometyx and Fainting - a phase IV clinical study of FDA data

Summary:

Fainting is reported as a side effect among people who take Cabometyx (cabozantinib s-malate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Zofran, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Fainting when taking Cabometyx. It is created by eHealthMe based on reports of 35,066 people who have side effects when taking Cabometyx from the FDA, and is updated regularly.

What is Cabometyx?

Cabometyx has active ingredients of cabozantinib s-malate. eHealthMe is studying from 35,069 Cabometyx users. Check the latest studies of Cabometyx.

What is Fainting?

Fainting (loss of consciousness and postural tone) is found to be associated with 2,451 drugs and 3,548 conditions by eHealthMe. Check the latest studies of Fainting.

On Aug, 09, 2026

35,066 people reported to have side effects when taking Cabometyx.
Among them, 43 people (0.12%) have Fainting.

Among these 43 people:

How long have people been on Cabometyx when they have Fainting? *

What is the gender of people who have Fainting when taking Cabometyx? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Fainting when taking Cabometyx? *

What are other drugs people take besides Cabometyx? *

What are other side effects people have besides Fainting? *

Diarrhea: 11 people, 25.58%
Dizziness: 11 people, 25.58%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 10 people, 23.26%
Weakness: 9 people, 20.93%
Nausea (feeling of having an urge to vomit): 8 people, 18.60%
Fatigue (feeling of tiredness): 8 people, 18.60%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 16.28%
Stomatitis (inflammation of mucous membrane of mouth): 7 people, 16.28%
Dehydration (dryness resulting from the removal of water): 7 people, 16.28%
High Blood Pressure: 7 people, 16.28%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 27 people, 62.79%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 9.30%
Hepatocellular Carcinoma (liver cancer): 3 people, 6.98%
Malignant Neoplasm Of Renal Pelvis (cancer tumour of ureter): 2 people, 4.65%
Periarthritis (inflammation of the external coats of an artery and of the tissues around the artery): 2 people, 4.65%
Endometrial Cancer: 2 people, 4.65%
Joint Pain: 2 people, 4.65%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 2.33%
Bladder Cancer: 1 person, 2.33%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 1 person, 2.33%

* Approximation only. Some reports may have incomplete information.

Do you take Cabometyx and have Fainting?

- Check whether Fainting is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabometyx:

Cabometyx (35,069 reports)

Fainting treatments and more:

Fainting (131,321 reports)

Browse all side effects of Cabometyx:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fainting:

Fainting (2,451 drugs)

Browse all the conditions that are associated with Fainting:

Fainting (3,548 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cabozantinib s-malate (the active ingredients of Cabometyx) and Cabometyx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.